You are here: Industry Insights > SARS-CoV-2

News List

New study suggests two paths toward ‘super immunity’ to COVID-19 WorldPharmaNews
January 26, 2022
New laboratory research from Oregon Health & Science University reveals more than one path toward robust immunity from COVID-19.
Pfizer and BioNTech publish data from two laboratory studies on COVID-19 vaccine-induced antibodies ability to neutralize SARS-CoV-2 Omicron variant WorldPharmaNews
January 26, 2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication of new results from two laboratory studies demonstrating that three doses of the Pfizer-BioNTech COVID-19 Vaccine...
Chung-Ang University researchers show gold-paved path towards faster COVID-19 diagnosis ExpressPharma
January 24, 2022
Researchers use gold nanoparticles to develop a new molecular diagnostic platform that considerably reduces the time required for COVID-19 detection.
The cellular response that protects pigs from COVID-19 WorldPharmaNews
January 24, 2022
Iowa State University scientists may have uncovered an important clue that sheds light on why pigs don’t get sick when exposed to the coronavirus.
COVID Can Affect Brains of Hospitalized Kids drugs.com
January 24, 2022
The coronavirus can leave more than 40% of children hospitalized for COVID-19 with headaches and other lingering neurological symptoms, a new study claims.
Persistent T cell response to omicron after infection and vaccination FirstWordPharma
January 20, 2022
The omicron variant can partly evade the antibody response provided by vaccination or infection with previous variants of SARS-CoV-2. However, T cells still recognise omicron...
Pfizer shares in vitro efficacy of novel COVID-19 oral treatment against omicron variant WorldPharmaNews
January 19, 2022
Pfizer Inc. (NYSE: PFE) today shared results from multiple studies demonstrating that the in vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets)...
Research team finds new dual benefit mode of action for a drug candidate to fight COVID-19 WorldPharmaNews
January 17, 2022
A research team led by Prof. Stephan Ludwig, a virologist at the Institute of Virology at the University of Münster, has found a new dual attack mode of action while working on the development of a drug candidate against SARS-CoV-2 infections.
GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab WorldPharmaNews
January 17, 2022
GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced that the US Government will purchase an additional 600,000 doses of sotrovimab...
Immune Biosolutions Lead Immunotherapy Neutralizes SARS-CoV-2 Variants contractpharma
January 10, 2022
IBIO123 is an inhaled antibody-based immunotherapy in phase 1 and 2 clinical development for the treatment of symptomatic SARS-CoV-2.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page